Histone Deacetylase Inhibitors Show Promise in Breast Cancer Clinical Trials

Breast cancer (搜索)搜索该疾病 (BRCA (搜索)搜索该疾病) remains a significant global health challenge, characterized by high malignancy and mortality rates among women. While conventional treatments like surgery, chemotherapy, and hormone therapy exist, the need for novel therapeutic approaches is pressing, especially for patients with poor responses to standard care. Epigenetic modifications, particularly histone deacetylation (HDAC (搜索)搜索该靶点), have emerged as key players in BRCA progression and drug resistance.

Clinical Trial Landscape

A recent analysis of the Trialtrove database revealed 97 clinical trials evaluating HDAC (搜索)搜索该靶点 inhibitors in BRCA (搜索)搜索该疾病. These trials span 24 regions, with the United States and China leading in the number of studies. The majority of trials are in early phases (Phase I and II: 87.6%), with a smaller proportion in Phase III (4.1%) and Phase IV (8.2%). Half of the registered Phase IV trials are focused on long-term safety, efficacy, and expanding approved indications.

Key HDAC Inhibitors in BRCA Trials

Chidamide查看药品详情 (Epidaza), an oral selective HDAC (搜索)搜索该靶点 inhibitor, is the most investigated in BRCA (搜索)搜索该疾病, with over half of its trials in Phase II and 20% reaching Phase IV. Vorinostat查看药品详情 (Zolinza), already FDA-approved for cutaneous T-cell lymphoma (CTCL), is the second most studied HDAC inhibitor. Entinostat查看药品详情 is also being evaluated, although trials involving this drug have largely been completed or terminated in BRCA. Other HDAC inhibitors are being explored, predominantly in Phase I or II trials.

Combination Therapy Strategies

Given the complexity of BRCA (搜索)搜索该疾病 and its molecular subtypes, combination therapies are gaining traction. Clinical trials are exploring HDAC (搜索)搜索该靶点 inhibitors in conjunction with chemotherapy, hormone therapy, targeted therapy, and immunotherapy. A significant number of trials (35) are evaluating HDAC inhibitors with hormone therapies, including selective ER modulators (e.g., Tamoxifen查看药品详情), aromatase inhibitors (e.g., Exemestane查看药品详情, Letrozole查看药品详情, and Anastrozole查看药品详情), and selective ER down-regulators (e.g., Fulvestrant查看药品详情).

Immunotherapy and Targeted Therapy Combinations

While immunotherapy is revolutionizing cancer treatment, trials combining HDAC (搜索)搜索该靶点 inhibitors with immunotherapy in BRCA (搜索)搜索该疾病 are still relatively limited. Most of these trials are in the planning or ongoing stages, indicating that this combination approach is in its early phases. Targeted therapies, combined with HDAC inhibitors, are also being investigated, with 21 trials exploring their effectiveness. These targeted strategies involve HER2 inhibitors (e.g., Trastuzumab查看药品详情), CDK4/6 inhibitors (e.g., Dalpiciclib, BEBT-209 and Ibrance), PARP inhibitors (e.g., Olaparib查看药品详情, Fluzoparib), tyrosine kinase inhibitors (e.g., Lapatinib), VEGFA inhibitor (e.g., Bevacizumab查看药品详情) or mTOR inhibitors (e.g., Everolimus).

Future Directions

Despite the progress, the mechanisms underlying the efficacy of HDAC (搜索)搜索该靶点 inhibitors in BRCA (搜索)搜索该疾病 remain largely unknown. Further research is needed to elucidate how these inhibitors modulate the tumor microenvironment, particularly in the context of immunotherapy. Insights from studies, such as the Phase II trial combining Entinostat查看药品详情 with Nivolumab in metastatic pancreatic cancer, which utilized RNA sequencing and CyTOF to explore immune profile changes, are expected to guide future research and treatment strategies.

In summary, clinical studies of HDAC (搜索)搜索该靶点 inhibitors in BRCA (搜索)搜索该疾病 are being conducted globally, with a focus on early-phase trials. Chidamide查看药品详情, Vorinostat查看药品详情, and Entinostat查看药品详情 are among the most studied drugs. Combination therapies, tailored to the molecular subtypes of BRCA, are a key focus. Future research into the mechanisms of HDAC inhibitor treatments will be crucial for optimizing their integration into BRCA treatment regimens.